Palbociclib-fulvestrant (PALBO-FUL) and everolimus-exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis

CANCER RESEARCH(2020)

引用 2|浏览66
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要